

Supplementary Table 8. Baseline characteristics of study participants for the p-STATA1-negative and p-STATA1-positive groups

Variables	Overall (n=44)	p-STATA1		P-value
		Negative (n=14)	Positive(n=30)	
Sex, Female n (%)	38 (86.4)	14 (100.0)	24 (80.0)	0.184
Age at enrollment (Years), Mean (SD)	42.23 (13.20)	41.50 (13.15)	42.57 (13.43)	0.806
Symptom duration at first visit (Years), Median [IQR]	1.00 [0.31, 3.00]	2.00 [0.50, 2.75]	1.00 [0.18, 3.00]	0.509
Dry eye, n (%)	20 (45.5)	8 (57.1)	12 (40.0)	0.460
Dry mouth, n (%)	29 (65.9)	9 (64.3)	20 (66.7)	1.000
Fever, n (%)	5 (11.4)	1 (7.1)	4 (13.3)	0.926
Fatigue, n (%)	10 (22.7)	1 (7.1)	9 (30.0)	0.194
Anti-SSA/Ro antibodies, n (%)	27 (61.4)	1 (7.1)	26 (86.7)	<0.001
Anti-SSB/La antibodies, n (%)	11 (25.0)	1 (7.1)	10 (33.3)	0.135
ANA, n (%)	26 (59.1)	3 (21.4)	23 (76.7)	0.002
dsDNA, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	N/A
RF(IU/mL), Mean (SD)	45.62 (87.46)	69.93 (151.40)	34.28 (25.46)	0.212
ESR (mm/h), Mean (SD)	22.07 (19.57)	15.93 (7.81)	24.93 (22.67)	0.158
CRP (g/L), Mean (SD)	5.20 (19.99)	1.22 (1.18)	7.05 (24.10)	0.373
IgG (g/L), Mean (SD)	16.65 (5.89)	13.32 (1.90)	18.20 (6.48)	0.009
IgM(g/L), Mean (SD)	1.57 (1.31)	1.43 (0.40)	1.63 (1.56)	0.633
IgA(g/L), Mean (SD)	2.54 (1.00)	2.15 (0.43)	2.71 (1.14)	0.084
C3 (g/L), Mean (SD)	1.07 (0.20)	1.04 (0.20)	1.09 (0.20)	0.393
C4 (g/L), Mean (SD)	0.23 (0.07)	0.22 (0.05)	0.23 (0.07)	0.487
Lymphadenopathy, n (%)	7 (15.9)	0 (0.0)	7 (23.3)	0.126
Active articular involvement, n (%)	16 (36.4)	2 (14.3)	14 (46.7)	0.081
Active cutaneous involvement, n (%)	9 (20.5)	0 (0.0)	9 (30.0)	0.058
Active pulmonary involvement, n (%)	10 (22.7)	1 (7.1)	9 (30.0)	0.194

Active renal involvement, n (%)	2 (4.5)	0 (0.0)	2 (6.7)	0.832
Active muscular involvement, n (%)	3 (6.8)	0 (0.0)	3 (10.0)	0.559
Active PNS involvement, n (%)	1 (2.3)	0 (0.0)	1 (3.3)	1.000
Active CNS involvement, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	N/A
Hematological involvement, n (%)	7 (15.9)	1 (7.1)	6 (20.0)	0.520
Focus score \geq 1, n (%)	14 (31.8)	0 (0.0)	14 (46.7)	0.006
